20240018224. ANTI-GPC3 ANTIBODY simplified abstract (Yamaguchi University)
Contents
ANTI-GPC3 ANTIBODY
Organization Name
Inventor(s)
Yukimi Sakoda of Yamaguchi (JP)
Tetsuya Nakatsura of Chiba (JP)
ANTI-GPC3 ANTIBODY - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240018224 titled 'ANTI-GPC3 ANTIBODY
Simplified Explanation
The present invention is an anti-gpc3 antibody that can specifically bind to gpc3 localized on a cell membrane, even in the form of a single chain antibody. It recognizes an epitope different from existing antibodies (e.g., gc33 and gc199). The invention also includes a CAR (chimeric antigen receptor) comprising the anti-gpc3 single chain antibody, an immunocompetent cell expressing the CAR, a gene of the anti-gpc3 antibody or the CAR, a vector comprising the anti-gpc3 antibody gene or the CAR gene, and a host cell in which the vector has been introduced. The invention further provides a method for specifically detecting gpc3 and a kit for specifically detecting gpc3. The antibody specifically binds to a human-derived gpc3 polypeptide localized on a cell membrane. CAR-immunocompetent cells prepared based on the CAR comprising such single chain antibody are useful for cancer immunotherapy.
- Anti-gpc3 antibody that recognizes a different epitope from existing antibodies and specifically binds to gpc3 on a cell membrane
- CAR comprising the anti-gpc3 single chain antibody
- Immunocompetent cells expressing the CAR
- Gene of the anti-gpc3 antibody or the CAR
- Vector comprising the anti-gpc3 antibody gene or the CAR gene
- Host cell in which the vector has been introduced
- Method for specifically detecting gpc3
- Kit for specifically detecting gpc3
Potential applications of this technology:
- Cancer immunotherapy using CAR-immunocompetent cells
- Specific detection of gpc3 in diagnostic tests for cancer
Problems solved by this technology:
- Lack of antibodies that can specifically bind to gpc3 on a cell membrane
- Limited options for cancer immunotherapy targeting gpc3
Benefits of this technology:
- Improved specificity in detecting and targeting gpc3
- Potential for more effective cancer immunotherapy
Original Abstract Submitted
an object of the present invention is to provide: an anti-gpc3 antibody that recognizes an epitope different from that for existing antibodies (e.g., gc33 and gc199) and can specifically bind, even in the form of single chain antibody, to gpc3 localized on a cell membrane; car comprising the anti-gpc3 single chain antibody; an immunocompetent cell expressing the car; a gene of the anti-gpc3 antibody or a gene of the car; a vector comprising the anti-gpc3 antibody gene or the car gene; a host cell in which the vector has been introduced; a method for specifically detecting gpc3; and a kit for specifically detecting gpc3. an antibody comprising particular heavy chain cdr1 to cdr3 and particular light chain cdr1 to cdr3 defined in claim , and specifically binding to a human-derived gpc3 polypeptide specifically binds to gpc3 localized on a cell membrane. car-immunocompetent cells prepared on the basis of car comprising such single chain antibody are useful for cancer immunotherapy.
